

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)



(10) International Publication Number
WO 2022/043538 A1

(51) International Patent Classification:

A61P 35/02 (2006.01) *C12Q 1/68* (2018.01)
A61K 31/00 (2006.01) *G01N 33/574* (2006.01)
C07K 16/28 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2021/073816

(22) International Filing Date:

27 August 2021 (27.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/072,113 29 August 2020 (29.08.2020) US

(71) Applicants: **ARGENX BV** [BE/BE]; Industriepark 7, 9052 Zwijnaarde (BE). **THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE** [US/US]; 1800 Grant Street, 8th Floor, Denver, CO 80203 (US).

(72) Inventors: **DE HAARD, Johannes**; 't Zwint 1, 4436 NA Oudelande (NL). **HULTBERG, Anna**; 8 Douglas Avenue, Hull, Massachusetts 02045 (US). **JACOBS, Julie**; Koningsstraat 71, 2381 Weelde (BE). **ZABROCKI, Piotr**; C/O Argenx BV, Industriepark Zwijnaarde 7, 9052 Zwijnaarde (BE). **SMITH, Clayton**; 12635 E. Montview Boulevard, Aurora, 80045 (US). **JORDAN, Craig**; 12635 E. Montview Boulevard, Aurora, 80045 (US).

(74) Agent: **BOULT WADE TENNANT LLP**; Salisbury Square House, 8 Salisbury Square, London Greater London EC4Y 8AP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))



WO 2022/043538 A1

(54) Title: METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR

(57) Abstract: Provided are an antibody or antigen binding fragment thereof that binds to CD70 for use in treating a myeloid malignancy in a human subject, who is resistant to BCL-2 inhibitor treatment and methods of treating a myeloid malignancy in a subject, said method comprising (a) selecting a human subject having a myeloid malignancy that has a reduced sensitivity or is refractory to a BCL-2 inhibitor; and (b) administering to the subject an antibody or antigen binding fragment thereof that binds to CD70. In certain embodiments, the myeloid malignancy is acute myeloid leukemia (AML). In certain embodiments, the antibody that binds to CD70 is cusatuzumab. In certain embodiments, a BCL-2 inhibitor is co-administered with the antibody or antigen binding fragment thereof that binds to CD70. In certain embodiments, the BCL-2 inhibitor is venetoclax.